- The FDA approved Bixlenvo, a once-daily HIV pill from Gilead for adults whose virus is suppressed but who cannot use currently available single-tablet treatment options.
- Bixlenvo combines bictegravir, the backbone of Biktarvy, with lenacapavir, a capsid inhibitor central to Gilead's HIV treatment and prevention strategy.
- Gilead said Bixlenvo's list price is $4,595 for a 30-day supply before discounts or rebates, in line with other daily single-tablet HIV treatments.
Quotes
“It fulfills an unmet need, particularly for individuals who are on complex regimens who just would not otherwise consolidate down to something really meaningful for them and prescribers”
“We want to build options that give people the opportunity to choose something that’s going to work for them and work for them for the long haul.”
Sources
- <a href="https://www.fiercepharma.com/pharma/gilead-christens-bixlenvo-fda-nod-new-hiv-treatment-combo-pill" hreflang="en">Gilead christens Bixlenvo with FDA nod for new HIV treatment combo tablet</a>FiercePharma
- FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsCNBC